Impact
A bigger and stronger platform
The AACR Annual Meeting 2026 convened more than 23,000 registrants from 74 countries and territories, showcasing a record number of nearly 250 clinical trials, including several practice-changing studies and 11 completed phase III trials. The program featured over 760 invited speakers from 24 countries, including 11 NextGen Stars selected through a competitive application process. More than 270 scientific sessions were live-streamed, and the meeting generated significant media coverage with over 190 registered reporters and 257 million impressions on social media. The Closing Plenary Session highlighted that fundamental insights into cancer biology are revealing new strategies to treat cancer and overcome treatment resistance. Plenary sessions explored generational trends and drivers of early-onset cancers, and spotlighted new treatment modalities including radiopharmaceuticals, next-generation biologics, and cellular immunotherapy. The meeting also featured special 'New Drugs on the Horizon' sessions with first disclosures of innovative therapeutics including novel CDK2 inhibitors, molecular glue degraders, and dual-payload antibody-drug conjugates.




